small molecule

JOURNAVX

SUZETRIGINE

Loss of exclusivityDecember 2040latest FDA-listed patent expiry

CompanyVERTEX PHARMACEUTICALS INC

Drug detail

Brand name	JOURNAVX
Active ingredient	SUZETRIGINE
Strength	50MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11834441	December 2040	substance, product

Regulatory exclusivity

Code	Expires
NCE	January 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from VERTEX PHARMACEUTICALS INC